Literature DB >> 16170367

The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase.

B Linggi1, Q C Cheng, A R Rao, G Carpenter.   

Abstract

The ErbB-4 receptor tyrosine kinase homo- and heterodimerizes following heregulin binding, which provokes increased levels of tyrosine autophosphorylation. Unique to the ErbB family, ErbB-4 is then proteolytically cleaved by alpha- and gamma-secretase to produce an 80 kDa intracellular domain (s80 ICD) fragment. This fragment is found in both the cytoplasm and nucleus of many normal and cancer cells and can interact with transcription factors in the cytoplasm and nucleus. Since the s80 ICD lacks ectodomain sequences known to play a major role in dimerization of ErbB family members, we asked whether the s80 ICD is an active tyrosine kinase. Here, we demonstrate that the s80 ICD is a constitutively active tyrosine kinase and can form homodimers. The s80 ICD is autophosphorylated in cells and can phosphorylate an exogenous substrate in vitro. Also, the s80 ICD can coassociate and dimers are detected by chemical crosslinking. This is the first example of constitutive kinase activation and dimerization totally within the cytoplasmic domain of an ErbB receptor and suggests that the s80 ICD may function to phosphorylate substrates in the cytoplasm or nucleus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16170367     DOI: 10.1038/sj.onc.1209003

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

2.  EGFs and ERBBs--brief history and prospects.

Authors:  David F Stern
Journal:  Semin Cell Dev Biol       Date:  2010-10-21       Impact factor: 7.727

Review 3.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

4.  Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase.

Authors:  Hao Zhang; Wei Shen; Don Rempel; John Monsey; Ilan Vidavsky; Michael L Gross; Ron Bose
Journal:  Mol Cell Proteomics       Date:  2011-03-21       Impact factor: 5.911

5.  The interaction of the ErbB4 intracellular domain p80 with α-enolase in the nuclei is associated with the inhibition of the neuregulin1-dependent cell proliferation.

Authors:  Satomi Yamada; Masaki Marutsuka; Miyabi Inoue; Jidong Zhang; Shin-Ichi Abe; Ken-Ichi Ishibashi; Naoto Yamaguchi; Ko Eto
Journal:  Int J Biochem Mol Biol       Date:  2014-05-15

6.  The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells.

Authors:  Rebecca S Muraoka-Cook; Melissa Sandahl; Carty Husted; Debra Hunter; Leah Miraglia; Shu-mang Feng; Klaus Elenius; H Shelton Earp
Journal:  Mol Biol Cell       Date:  2006-07-12       Impact factor: 4.138

Review 7.  Trafficking of receptor tyrosine kinases to the nucleus.

Authors:  Graham Carpenter; Hong-Jun Liao
Journal:  Exp Cell Res       Date:  2008-10-11       Impact factor: 3.905

8.  ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms.

Authors:  Daria Krivosheya; Lucia Tapia; Joshua N Levinson; Kun Huang; Yunhee Kang; Rochelle Hines; Annie K Ting; Ann Marie Craig; Lin Mei; Shernaz X Bamji; Alaa El-Husseini
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

Review 9.  Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.

Authors:  Wei Wang; Hua-Fu Zhao; Teng-Fei Yao; Hao Gong
Journal:  Invest New Drugs       Date:  2018-10-24       Impact factor: 3.850

10.  ErbB4 promotes cyclooxygenase-2 expression and cell survival in colon epithelial cells.

Authors:  Mark R Frey; Valda C Hilliard; Matthew T Mullane; D Brent Polk
Journal:  Lab Invest       Date:  2010-06-28       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.